Anti-CD20 Antibody Therapy for Sjogren's Syndrome

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in treating patients with Sjogren's syndrome (SS). Rituximab is a laboratory-made antibody currently used to treat some kinds of lymphoma. Rituximab may also help people with SS, a disease of the immune system. However, the safety of rituximab in SS patients must first be established.

Clinical Trial Description

SS is the second most common autoimmune disease; it is caused by immune cells attacking and destroying the glands that produce tears and saliva, and occurs more often in women than in men. Currently, there are no established disease-modifying treatments for SS. Traditional treatment strategies for SS primarily address dryness symptoms. Rituximab targets the CD20 antigen on the surface of B cells, and was approved in 1997 for the treatment of patients with low-grade or follicular B-cell non-Hodgkin's lymphoma. In a small study, rituximab was also shown to relieve the symptoms of rheumatoid arthritis. Because SS is associated with the development of B cell-related cancers and rituximab has the potential to treat autoimmune disease, rituximab may alleviate the symptoms of SS. This study will evaluate the safety of rituximab in people with SS.

This study will last 1 year. At 4 and 2 weeks before the start of the study, patients will undergo medical and medication history assessment, a physical exam, blood and urine collection, rheumatologic evaluation, an eye exam, and salivary gland tests. The screening visit 4 weeks before study start will also include an electrocardiogram (ECG), a chest x-ray, and a tuberculosis exam. Patients will receive IV rituximab at study entry and at Week 2; blood collection will occur prior to infusion and post-infusion for pharmacokinetics studies. There will be 6 follow-up study visits that will occur at Weeks 4, 8, 14, 26, 30, and 52. Blood and urine collection; a physical exam; rheumatologic evaluation; and eye, skin, and salivary gland tests will occur at selected study visits. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00101829
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 1
Start date	April 2004
Completion date	August 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Completed	`NCT04968912` - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)	Phase 2
Completed	`NCT03203382` - Corneal Nerve Structure in Sjogren's
Completed	`NCT00809003` - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease	N/A
Completed	`NCT00023491` - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells	N/A
Completed	`NCT05005806` - Fish Oil (Omega 3 ) in Sjogren's Syndrome	Phase 2/Phase 3
Enrolling by invitation	`NCT03436576` - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye	Phase 3
Terminated	`NCT04143841` - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease	N/A
Completed	`NCT03611283` - Topical Management of Xerostomia With Dry Mouth Products	N/A
Recruiting	`NCT06104124` - A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity	Phase 3
Recruiting	`NCT05115487` - Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
Recruiting	`NCT06437652` - An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
Recruiting	`NCT05383677` - Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome	Phase 2
Not yet recruiting	`NCT03938207` - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed	`NCT04546542` - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Completed	`NCT04239521` - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting	`NCT05085431` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome	Early Phase 1
Completed	`NCT00565526` - Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
Completed	`NCT01369589` - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness	Phase 1/Phase 2
Completed	`NCT00001953` - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.